MCID: ANG005
MIFTS: 56

Anogenital Venereal Wart

Categories: Infectious diseases, Oral diseases, Reproductive diseases, Skin diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Anogenital Venereal Wart

MalaCards integrated aliases for Anogenital Venereal Wart:

Name: Anogenital Venereal Wart 11 14 16
Genital Warts 11 53 41 2 14 33
Condylomata Acuminata 43 71 33
Condyloma Acuminatum 11 75
Anogenital Warts 11 33
Anogenital Human Papilloma Virus Infectious Disease 11
Genital Wart Virus Infectious Disease 11
Verrucae Anogenitales 33
Verrucae Genitales 33
Venereal Warts 33
Venereal Wart 11

Classifications:



External Ids:

Disease Ontology 11 DOID:11168
ICD9CM 34 078.11
MeSH 43 D003218
NCIt 49 C2960 C4820
SNOMED-CT 68 240542006 302812006
ICD10 31 A63.0
UMLS 71 C0009663 C0554632

Summaries for Anogenital Venereal Wart

MedlinePlus: 41 Genital warts are a sexually transmitted disease (STD) caused by the human papillomavirus (HPV). The warts usually appear as a small bump or group of bumps in the genital area. They are flesh-colored and can be flat or look bumpy like cauliflower. Some genital warts are so small you cannot see them. In women, the warts usually occur in or around the vagina, on the cervix, or around the anus. In men, genital warts are less common. They may have warts on the tip of the penis, around the anus, or on the scrotum, thigh, or groin. You can get genital warts during oral, vaginal, or anal sex with an infected partner. Correct usage of latex condoms greatly reduces, but does not completely eliminate, the risk of catching or spreading HPV. If your or your partner is allergic to latex, you can use polyurethane condoms. The most reliable way to avoid infection is to not have anal, vaginal, or oral sex. HPV vaccines may help prevent some of the HPV infections that cause genital warts. Your health care provider usually diagnoses genital warts by seeing them. The warts might disappear on their own. If not, your health care provider can treat or remove them. HPV stays in your body even after treatment, so warts can come back. Dept. of Health and Human Services Office on Women's Health

MalaCards based summary: Anogenital Venereal Wart, also known as genital warts, is related to verrucous carcinoma and papilloma, and has symptoms including anogenital warts, fever and pruritus. An important gene associated with Anogenital Venereal Wart is IFNA1 (Interferon Alpha 1), and among its related pathways/superpathways are Innate Immune System and Disease. The drugs Imiquimod and Cantharidin have been mentioned in the context of this disorder. Affiliated tissues include skin of vagina, cervix and skin, and related phenotypes are homeostasis/metabolism and immune system

Disease Ontology: 11 A viral infectious disease that results in infection located in skin of vagina, cervix, uterus, anus, penis, scrotum, mouth, or throat, has material basis in human papillomaviruses (types 6 and 11), which are transmitted by direct contact with the skin during oral, genital, or anal sex with an infected partner. The infection has symptom anogenital warts.

CDC: 2 HPV is a common virus that can lead to certain types of cancer later in life. Getting your 11-12 year-old child two doses of the HPV vaccine can prevent these cancers.

Wikipedia: 75 Genital warts are a sexually transmitted infection caused by certain types of human papillomavirus... more...

Related Diseases for Anogenital Venereal Wart

Diseases related to Anogenital Venereal Wart via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 704)
# Related Disease Score Top Affiliating Genes
1 verrucous carcinoma 31.3 TP53 GP5 CDKN2A
2 papilloma 31.3 UBE3A TP53 CDKN2A CCR6
3 syphilis 30.9 CD8A CD4 CCR6
4 common wart 30.9 TP53 TMC8 TLR7 IFNA1 CD4
5 squamous cell papilloma 30.8 TP53 GP5 CDKN2A
6 keratosis, seborrheic 30.6 TP53 TMC8 CDKN2A
7 inflammatory bowel disease 1 30.6 TLR4 H2AC18 CCR6
8 primary syphilis 30.6 CD8A CD4
9 penile benign neoplasm 30.5 TP53 GP5 CDKN2A
10 phimosis 30.5 TP53 GP5 CDKN2A
11 vulva squamous cell carcinoma 30.5 TP53 GP5 CDKN2A
12 autoimmune polyendocrine syndrome 30.5 IFNA1 CD4 CCR6
13 adenocarcinoma in situ 30.5 TP53 GP5 CDKN2A
14 anal squamous cell carcinoma 30.5 TP53 H2AC18 CDKN2A CD8A CD4
15 molluscum contagiosum 30.5 TLR9 TLR3 IFNB1
16 lichen sclerosus et atrophicus 30.5 TLR4 CD8A
17 panniculitis 30.4 CD8A CD4 CCR6
18 croup 30.4 IFNB1 IFNA1 CD4
19 acanthoma 30.4 TP53 TMC8 CDKN2A
20 suppressor of tumorigenicity 3 30.4 UBE3A TP53 CDKN2A
21 urethritis 30.4 TLR4 CD8A CD4
22 chronic cervicitis 30.4 TP53 GP6 GP5 CDKN2A
23 vulva cancer 30.4 TP53 GP5 CDKN2A
24 focal epithelial hyperplasia 30.3 TP53 TMC8 GP6 GP5
25 mumps 30.3 TLR3 IL2 IFNB1 IFNA1
26 vulvar disease 30.3 TP53 GP5 CDKN2A
27 scabies 30.3 CD8A CD4 CCR6
28 urinary tract infection 30.3 TLR4 H2AC18 CD4 CCR6
29 herpes simplex 30.3 TLR9 TLR3 IFNB1 IFNA1 CD8A
30 cellulitis 30.3 CD8A CD4 CCR6
31 vitiligo-associated multiple autoimmune disease susceptibility 1 30.3 IL2 CD8A CD4 CCR6
32 hepatitis a 30.3 TLR4 TLR3 IFNA1 CD4
33 panuveitis 30.3 CD8A CD4 CCR6
34 lymphangioma 30.2 TP53 H2AC18 CD8A CD4 CCR6
35 vaginitis 30.2 TLR4 CD4 CCR6
36 rubella 30.2 TLR4 TLR3 IL2 IFNB1
37 penile cancer 30.2 UBE3A TP53 GP6 GP5 CDKN2A CD8A
38 head and neck cancer 30.2 TP53 H2AC18 CDKN2A CD8A CD4 CCR6
39 cervix uteri carcinoma in situ 30.2 TP53 GP6 GP5 CDKN2A CD4
40 lymphoma, hodgkin, classic 30.2 TP53 IL2 H2AC18 CCR6
41 acquired immunodeficiency syndrome 30.1 TP53 NCR1 IL2 IFNA1 CD4
42 basal cell carcinoma 30.1 TP53 TLR7 H2AC18 CDKN2A CCR6
43 vaginal cancer 30.1 UBE3A TP53 GP5 CDKN2A CD8A CD4
44 deficiency anemia 30.1 TP53 IL2 IFNA1 H2AC18 CD8A CD4
45 colitis 30.1 TLR9 TLR4 IL2 CD4 CCR6
46 contact dermatitis 30.0 IL2 CD8A CD4 CCR6
47 systemic scleroderma 30.0 IL2 IFNA1 H2AC18 CD8A CD4 CCR6
48 myelodysplastic syndrome 30.0 TP53 H2AC18 CDKN2A CD8A CD4 CCR6
49 vaccinia 30.0 TP53 IL2 IFNB1 IFNA1
50 poliomyelitis 29.9 TLR3 IL2 IFNB1 IFNA1 CD8A CD4

Graphical network of the top 20 diseases related to Anogenital Venereal Wart:



Diseases related to Anogenital Venereal Wart

Symptoms & Phenotypes for Anogenital Venereal Wart

Symptoms:

11
  • anogenital warts

UMLS symptoms related to Anogenital Venereal Wart:


fever; pruritus; pelvic pain; penile warts

GenomeRNAi Phenotypes related to Anogenital Venereal Wart according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.14 CCR6 CD4 CD8A CDKN2A GP5 GP6
2 no effect GR00402-S-2 10.14 CCR6 CD4 CDKN2A GP5 GP6 H2AC18

MGI Mouse Phenotypes related to Anogenital Venereal Wart:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.16 CCR6 CD4 CDKN2A GP5 GP6 IFNB1
2 immune system MP:0005387 10.09 CCR6 CD4 CD8A CDKN2A GP6 IFNA1
3 normal MP:0002873 9.97 CCR6 CD8A GP5 IFNA1 IFNA6 IFNB1
4 neoplasm MP:0002006 9.91 CDKN2A IFNB1 IL2 TLR3 TLR4 TLR7
5 hematopoietic system MP:0005397 9.58 CCR6 CD4 CD8A CDKN2A GP6 IFNA1
6 respiratory system MP:0005388 9.56 CDKN2A IFNA1 IFNA6 IL2 TLR3 TLR4

Drugs & Therapeutics for Anogenital Venereal Wart

Drugs for Anogenital Venereal Wart (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 51)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Imiquimod Approved, Investigational Phase 4 99011-02-6 57469
2
Cantharidin Approved, Investigational Phase 4 56-25-7 2545
3
Cianidanol Approved, Withdrawn Phase 4 154-23-4 9064
4
Zinc cation Approved, Experimental, Investigational Phase 4 7440-66-6, 23713-49-7 32051
5
Epicatechin Investigational Phase 4 490-46-0 58571364 72276
6 Tea Phase 4
7 Adjuvants, Immunologic Phase 4
8
Podophyllin Approved Phase 3 9000-55-9
9
Petrolatum Approved, Investigational Phase 3 8009-03-8
10
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
11
Picropodophyllin Approved, Investigational Phase 3 518-28-5, 477-47-4 10607 72435
12 Insulin, Globin Zinc Phase 3
13
Insulin Phase 3
14 Keratolytic Agents Phase 3
15 Dermatologic Agents Phase 3
16 Antiviral Agents Phase 3
17 Anti-Infective Agents Phase 3
18 interferons Phase 3
19 Antirheumatic Agents Phase 3
20 Alkylating Agents Phase 3
21 Antineoplastic Agents, Alkylating Phase 3
22 Immunosuppressive Agents Phase 3
23 Interferon-gamma Phase 3
24 Antimitotic Agents Phase 3
25 Tubulin Modulators Phase 3
26 Immunologic Factors Phase 3
27 Vaccines Phase 3
28
Nitric Oxide Approved Phase 2 10102-43-9 145068
29
Sodium citrate Approved, Investigational Phase 2 68-04-2 23431961
30
Coal tar Approved Phase 2 8007-45-2
31
Citric acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
32
Ranpirnase Investigational Phase 1, Phase 2 196488-72-9
33 Ammonium trichloro(dioxoethylene-O,O'-)tellurate Phase 1, Phase 2
34 Radiation-Protective Agents Phase 1, Phase 2
35 Reverse Transcriptase Inhibitors Phase 1, Phase 2
36 Protective Agents Phase 1, Phase 2
37 Pharmaceutical Solutions Phase 1, Phase 2
38 Calcium, Dietary Phase 2
39 Anticoagulants Phase 2
40 Citrate Phase 2
41 Chelating Agents Phase 2
42
Calcium Nutraceutical Phase 2 7440-70-2 271
43
Cidofovir Approved Phase 1 113852-37-2 60613
44
Aminolevulinic acid Approved 106-60-5 137
45
Formaldehyde Approved, Vet_approved 50-00-0 712
46
Ethanol Approved 64-17-5 702
47 Photosensitizing Agents
48 Contraceptive Agents
49 Interleukin-4
50 Anti-Infective Agents, Local

Interventional clinical trials:

(show top 50) (show all 99)
# Name Status NCT ID Phase Drugs
1 Multicenter, Randomised, Double-blind, Vehicle-controlled Study Comparing Recurrence Rate Following Imiquimod 5% Cream or Vehicle 3 Times Per Week for 4 Weeks Prior to Ablative Therapy in Subjects Suffering From External Ano-Genital Warts Completed NCT00189293 Phase 4 Imiquimod
2 Alternate Dosing Schedules Study for HPV Vaccine Completed NCT00862810 Phase 4
3 An Open-Label, Single-Center Phase I (Phase IV/ USA) Study to Assess the Pharmacokinetic Profile of Topically Applied Veregen® 15% in Patients With External Genital and Perianal Warts Compared With Oral Intake of a Green Tea Beverage Completed NCT01082302 Phase 4 Polyphenon E (Veregen) 15% ointment
4 Trichloroacetic Acid Versus Cantharone for the Treatment of Perenial Warts Completed NCT03625960 Phase 4 Cantharidin;Trichloroacetic Acid
5 A Randomized Controlled Trial to Examine the Effectiveness of 400 mg of Oral Zinc Gluconate as Adjunctive Therapy for Ano-genital Warts Terminated NCT01468636 Phase 4 Oral Zinc;Placebo
6 The Efficacy of Intralesional Measles, Mumps, Rubella (MMR) Vaccine, Intralesional Candidal Antigen and Topical Podophyllin in Treatment of Genital Warts: A Comparative Study Unknown status NCT03853785 Phase 3 Topical Podophyllin
7 Efficacy Study of the Quadrivalent Human Papilloma Virus (HPV) Vaccine to Prevent Recurrence of External Genital Warts (EGW) in Patients Who Were Cured in the First Place Unknown status NCT03296397 Phase 3
8 Betaglucin 0.2% Gel Versus Imiquimod Cream 5% in the Treatment of Anogenital Warts in 102 Individuals Older Than 18 Years. Unknown status NCT03901690 Phase 3 Betaglucin soluble gel 0.2%;Imiquimod 5% cream
9 Comparison Between Tuberculin Vaccine and Cryotherapy in the Treatment of Genital Wart Patients Unknown status NCT03153566 Phase 3
10 A Randomized, Double-Blind, Three-Arm Parallel-Group, Placebo-Controlled Phase 3 Trial to Investigate the Clinical Efficacy and Safety of Polyphenon E in the Treatment of External Genital Warts Completed NCT00449982 Phase 3 Polyphenon E Ointment 10%, Polyphenon E Ointment 15%
11 A Phase 3, Randomized, Double-blind, Placebo-controlled, Multi-center, Efficacy and Safety Study of Imiquimod Creams in the Treatment of External Genital Warts Completed NCT00674739 Phase 3 Imiquimod;3.75% imiquimod cream;placebo cream
12 A Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts Completed NCT00735462 Phase 3 2.5% imiquimod cream;3.75% imiquimod cream;Placebo cream
13 A Study to Evaluate the Efficacy of Quadrivalent HPV Vaccine in Reducing the Incidence of HPV 6-, 11-, 16-, and 18-Related CIN, AIS, and Cervical Cancer, and HPV 6-, 11-, 16-, and 18-Related External Genital Warts, Vulvar Intraepithelial Neoplasia Vaginal Intraepithelial Neoplasia, Vulvar Cancer, and Vaginal Cancer in 16- to 23-Year-Old Women Completed NCT00092521 Phase 3
14 Phase III Study of the Treatment of Genital Warts by Low Dose Cyclophosphamide Completed NCT00999986 Phase 3 cyclophosphamide
15 Immunogenicity and Safety of Quadrivalent HPV L1 Virus-Like Particle (VLP) Vaccine in 16- to 23-Year-Old Women When Administered Alone or Concomitantly With Hepatitis B Vaccine (Recombinant)--the F.U.T.U.R.E. Study (Females United to Unilaterally Reduce Endo/Ectocervical Disease Completed NCT00517309 Phase 3
16 A Controlled Trial to Assess the Immunogenicity of a Proposed Paediatric Dosing Schedule of Human Papillomavirus Vaccine Completed NCT00501137 Phase 3
17 A Randomized, International, Double-Blinded (With In-House Blinding), Controlled With GARDASIL, Dose-Ranging, Tolerability, Immunogenicity, and Efficacy Study of a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered to 16- to 26- Year-Old Women Completed NCT00543543 Phase 3
18 A Study to Demonstrate Immunogenicity and Tolerability of Gardasil (V501) Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in Preadolescents, and To Determine End-Expiry Specifications for the Vaccine Completed NCT00092495 Phase 3
19 A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of 9vHPV (V503), a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to 26-Year-Old Women Completed NCT01651949 Phase 3
20 A Phase III, Randomized, International, Placebo-Controlled, Double-Blind Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, Given to Females 12-26 Years of Age Who Have Previously Received GARDASIL™ Completed NCT01047345 Phase 3
21 An Open-Label Phase III Clinical Trial to Study the Immunogenicity and Tolerability of GARDASIL®9 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Adult Women (27- to 45-Year-Olds) Compared to Young Adult Women (16 to 26 Year Olds) Completed NCT03158220 Phase 3
22 Immunogenicity and Safety of Gardasil (V501) Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in Consistency Lots for 16- to 23-Year-Old Women With and Additional Immunogenicity Bridge to the Monovalent HPV 16 Vaccine Pilot Manufacturing Lot Study-The F.U.T.U.R.E. Study (Females United to Unilaterally Reduce Endo/Ectocervical Disease) Completed NCT00092482 Phase 3
23 An Investigational Vaccine in Reducing the Incidence of Anogenital Warts in Young Men Completed NCT00090285 Phase 3
24 A Phase III Open-label Safety and Immunogenicity Study of GARDASIL™9 Administered to 9- to 26-Year-Old Females and Males in Vietnam Completed NCT03546842 Phase 3
25 Open Controlled Randomized Study of the Efficacy and Safety of Ingaron (Interferon-gamma) in the Treatment of Anogenital Warts (Phase III) Completed NCT05156541 Phase 3 Interferon gamma human recombinant (IFN-G)
26 A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo- Controlled, Study of Hyloris Developments' Podofilox Topical Gel 0.5% Compared to Allergan's Condylox® Gel 0.5% in Male and Female Patients With External Anogenital Warts. Completed NCT03532776 Phase 3 Podofilox Gel 0.5%;Condylox Topical Gel 0.5%;Placebo Gel
27 A Randomized, Double-Blind and Positive-Controlled Phase 3 Study to Evaluate the Immunogenicity and Safety of the 4-valent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (Hansenula Polymorpha) and 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 20-45 Years Completed NCT04425291 Phase 3
28 Efficacy of Glizigen-Viudid in the Treatment of External Anogenital Warts in Children and Adolescents. Completed NCT01111344 Phase 3
29 A Randomized, Double-Blind and Positive-Controlled Phase 3 Study to Evaluate the Immunogenicity and Safety of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged16-26 Years Completed NCT05372016 Phase 3
30 Prophylactic Vaccines as Therapy: Prevention of Recurrence of Extensive Genital Warts Recruiting NCT02750202 Phase 3
31 A Phase 3 Open-Label Immunogenicity and Safety Study of 2-Dose Regimens of V503, a 9-Valent Human Papillomavirus (HPV) Vaccine in Chinese Males 9 Through 14 Years Old and 3-Dose Regimen of V503 in Chinese Males 9 Through 19 Years Old Recruiting NCT05314023 Phase 3
32 Evaluating the Immunogenicity and Safety of 9-valent Human Papillomavirus(Type6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine in Chinese Females Aged 9 to 45 Years: A Phase 3, Open-label, Non-randomised Clinical Trial Recruiting NCT04895020 Phase 3
33 A Multicenter,Randomized,Blind and Positive-Controlled Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 20-45 Years Recruiting NCT04422366 Phase 3
34 Evaluating the Immunogenicity and Safety of Quadrivalent Human Papillomavirus Recombinant Vaccine (Type 6, 11, 16, 18) in Healthy Chinese Female Subjects Aged 9 to 26 Years: A Phase 3, Open-label, Non-randomized Clinical Trial Recruiting NCT05027776 Phase 3
35 A Randomized, Worldwide, Placebo-Controlled, Double-Blind Study to Investigate the Safety, Immunogenicity, and Efficacy on the Incidence of HPV 16/18-Related CIN 2/3 or Worse of the Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in 16- to 23-Year Old Women - The FUTURE II Study (Females United to Unilaterally Reduce Endo/Ectocervical Disease) Active, not recruiting NCT00092534 Phase 3
36 A Randomized, Single-blind Study to Compare Immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58) Vaccine(E.Coli) (Xiamen Innovax Biotech Co.,Ltd.) Versus Gardasil®9 (Merck & Co., Inc.) in Healthy Females 18-26 Years of Age Active, not recruiting NCT04782895 Phase 3
37 Immunogenicity Non-inferiority Immuno-bridging Study of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58) Vaccine (E.Coli) in Healthy Population Aged 9-17 Years Old vs Aged 18-26 Years Old Active, not recruiting NCT05056402 Phase 3
38 A Multicenter, Randomized, Double-Blind, Controlled (Bivalent Human Papillomavirus Vaccine (16,18 Type)(E. Coli)) Phase III Clinical Trial to Estimate Efficacy, Immunogenicity and Safty of the Recombinant Human Papillomavirus Vaccine (6,11,16,18,31,33,45,52,58 Type) (E.Coli) in Healthy Women Aged 18 to 45 Years Active, not recruiting NCT04537156 Phase 3
39 A Phase III, Randomized, Blinded, Positive-controlled Study to Compare the Immunogenicity of Zerun 9-valent Human Papillomarivus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine (Pichia Pastoris) in Healthy Female Subjects Aged 16-26 Years. Active, not recruiting NCT05580341 Phase 3
40 A Phase 3, Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9vHPV Vaccine in Japanese Males, 16 to 26 Years of Age. Active, not recruiting NCT04635423 Phase 3
41 A Multicenter,Randomized, Placebo-Controlled, and Double-blind Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity and Safety of Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Aged 18-45 Years Not yet recruiting NCT05584332 Phase 3
42 Randomised, Blind and Placebo-controlled Trial for the CIGB-300 Perilesional Application in Two Dose Levels in the Recurrent and Non Recurrent Genital Condyloma Terminated NCT01639638 Phase 2, Phase 3 PROAPOPTOTIC PEPTIDE CIGB 300
43 A Phase II, Multicenter, Randomized, Double Blind, Vehicle Controlled Study Evaluating the Efficacy and Tolerability of AS101 15% Gel for External Genital Warts. Unknown status NCT01943630 Phase 2 15% AS101 gel;Vehicle
44 A Phase 2, Multi-center, Double-blind, Randomized, Vehicle-controlled, Ascending Dose Study Assessing Tolerability, Safety, and Efficacy of Topical NVN1000 in Subjects With External Genital Warts and Perianal Warts Completed NCT02462187 Phase 2 NVN1000 8% Gel;NVN1000 16%;Vehicle;NVN1000 24%
45 Phase II Clinical Study, Double Blinded, Multicentric, Controlled Against Placebo, in Parallel Groups, to Evaluate the Efficacy and Safety of a Topical Product Containing Ranpirnase in Genital Warts - HPV Completed NCT02535104 Phase 1, Phase 2 Ranpirnase;Vehicle
46 A Randomized, Vehicle Controlled, Active Comparator, Parallel Group Study to Evaluate Efficacy, Safety, and Tolerability of Topical LFX453 Formulations in Patients With External Genital Warts (EGWs) Completed NCT02482428 Phase 2 Investigational Treatment;Aldara
47 A Phase 2, Double-Blind, Placebo-Controlled Study to Determine the Dose Regimen, Efficacy, Safety, and Tolerability of VP-102 in Subjects With External Genital Warts Completed NCT03981822 Phase 2
48 A Double-Blind, Vehicle Controlled, Randomized, Phase II Study of SR-T100 Gel on External Genital Warts/Condyloma Acuminate (EGWs) Completed NCT01796821 Phase 2 Vehicle gel;SR-T100 gel with 1.0 % SM;SR-T100 gel with 2.3% SM
49 A Phase I/II, Open Labeled, Uncontrolled, Single Center Study of Topical AS101 for External Genital Warts Completed NCT01555112 Phase 1, Phase 2 Topical AS101
50 A Phase 2, Randomized, Vehicle-Controlled, Double-Blind, Parallel-Group Study to Explore the Pharmacodynamics, Safety and Efficacy of Topical Omiganan in Patients With External Genital Warts Completed NCT02849262 Phase 2 Omiganan (CLS001) topical gel;Vehicle topical gel

Search NIH Clinical Center for Anogenital Venereal Wart

Inferred drug relations via UMLS 71 / NDF-RT 50 :


imiquimod
Interferon Alfa-2b
Interferon Alfa-n3
podophyllin
PODOPHYLLIN PWDR

Cochrane evidence based reviews: condylomata acuminata

Genetic Tests for Anogenital Venereal Wart

Anatomical Context for Anogenital Venereal Wart

Organs/tissues related to Anogenital Venereal Wart:

FMA: Skin Of Vagina
MalaCards : Cervix, Skin, Uterus, T Cells, Thymus, Bone Marrow, Tongue

Publications for Anogenital Venereal Wart

Articles related to Anogenital Venereal Wart:

(show top 50) (show all 5024)
# Title Authors PMID Year
1
Immunothrombotic Mechanisms Induced by Ingenol Mebutate Lead to Rapid Necrosis and Clearance of Anogenital Warts. 62 41
36362165 2022
2
Establishing a prediction model for recurrence of condyloma acuminatum. 62 41
36138469 2022
3
University Students' Knowledge about the Relation between Human Papillomavirus (HPV) and Head and Neck and Oral Cancers. 62 41
36037126 2022
4
Dermal and transdermal delivery of protein pharmaceuticals: lipid-based delivery systems for interferon alpha. 53 62
10512792 1999
5
Therapeutic approaches to papillomavirus infections. 53 62
9098642 1997
6
Status of local cellular immunity in interferon-responsive and -nonresponsive human papillomavirus-associated lesions. 53 62
8946632 1996
7
Response to interferon treatment decreases with epidermal dedifferentiation in condylomas. 53 62
8863992 1996
8
Intralesional beta-interferon treatment of cervical intraepithelial neoplasia associated with human papillomavirus infection. 53 62
8016908 1994
9
[Interferons, a class of cytokines with a large therapeutic activity range]. 53 62
7515733 1993
10
A Rare Case of Vulvar Myiasis in a Mentally Subnormal Young Woman. 62
36457453 2022
11
Role of chemokines in HPV-induced cancers. 62
36402301 2022
12
--Human papillomavirus and Chinese international students in the United States: attitudes, knowledge, vaccination trends, healthcare behaviors, and sexual activity. 62
33705223 2022
13
Human Papillomavirus, Related Diseases, and Vaccination: Knowledge and Awareness Among Health Care Students and Professionals in Nepal. 62
33939117 2022
14
Condyloma acuminatum of the urinary bladder with underlying squamous cell carcinoma: a case report. 62
36457102 2022
15
Bleomycin-based electrochemotherapy for the treatment of a Buschke-Löwenstein tumor (perianal giant condyloma) in an HIV-positive kidney transplant recipient: A case report. 62
36406182 2022
16
Squamous Cell Carcinoma Arising from Perianal Buschke-Lowenstein Tumor (Giant Condyloma Acuminatum): Comprehensive Literature Review. 62
34694593 2022
17
Human papillomavirus infections in low-grade squamous intraepithelial lesion in Peruvian pregnant woman: A cross-sectional cytology-based study. 62
36381406 2022
18
Development of field-applicable endogenous internally controlled recombinase-aided amplification (EIC-RAA) assays for the detection of human papillomavirus genotypes 6 and 11 using sample releasing agent. 62
36387484 2022
19
Human Papillomavirus E1 Protein Regulates Gene Expression in Cells Involved in Immune Response. 62
36418714 2022
20
Cost-effectiveness and epidemiological impact of gender-neutral HPV vaccination in Spain. 62
36347243 2022
21
Anal Human Papillomavirus Infection in Kidney Transplant Recipients Compared With Immunocompetent Controls. 62
35438132 2022
22
Photodynamic therapy in the treatment of condyloma acuminata: A systematic review of clinical trials. 62
36420589 2022
23
Stated preferences for human papillomavirus vaccination for adolescents in selected communities in Ibadan, Southwest Nigeria: A discrete choice experiment. 62
36383765 2022
24
Alteration of Na/H exchange regulatory factor-1 protein levels in anogenital lesions positive for mucosal high-risk human papillomavirus type 16. 62
36179457 2022
25
Intralesional immunotherapy for non-genital warts: A systematic review and meta-analysis. 62
35962514 2022
26
Health associations for male survivors of unwanted and non-consensual sex. 62
34467798 2022
27
Immunogenicity and safety of two novel human papillomavirus 4- and 9-valent vaccines in Chinese women aged 20-45 years: A randomized, blinded, controlled with Gardasil (type 6/11/16/18), phase III non-inferiority clinical trial. 62
36283897 2022
28
Coexistence of condyloma acuminatum and extramammary Paget's disease on penis and scrotum: A rare case report. 62
36397375 2022
29
High versus low dose oral isotretinoin in the treatment of cutaneous and genital warts. 62
36346210 2022
30
The Clinical and Economic Impact of a Nonavalent Versus Bivalent Human Papillomavirus National Vaccination Program in Taiwan. 62
36116338 2022
31
Could the human papillomavirus recombinant vaccine be a new valid approach in the management of ano-genital warts? 62
34904623 2022
32
Effectiveness, immunogenicity, and safety of the quadrivalent HPV vaccine in women and men aged 27-45 years. 62
35853188 2022
33
Topical hydrogen peroxide solution 40% in treatment of plane wart. 62
35064617 2022
34
Changes in the Prevalence of Human Papillomavirus Genotypes in Genital Warts Since the Introduction of Prophylactic Vaccines. 62
35688211 2022
35
Intralesional injection of purified protein derivative versus Candida antigen in treatment of genital warts. 62
36056784 2022
36
A nationwide longitudinal study on risk factors for progression of anal intraepithelial neoplasia grade 3 to anal cancer. 62
35657350 2022
37
Pemphigus vegetans misdiagnosed as condylomata acuminata: A case report. 62
36258762 2022
38
Vaccination with human alphapapillomavirus-derived L2 multimer protects against human betapapillomavirus challenge, including in epidermodysplasia verruciformis model mice. 62
36070626 2022
39
Ten-Year Trend in Emergency Department Visits for Sexually Transmitted Infections among Adolescents: A Retrospective Cross-Sectional Study in Italy. 62
36361087 2022
40
Development and psychometric properties of the human papillomavirus-quality of life (HPV-QoL) questionnaire to assess the impact of HPV on women health-related-quality-of-life. 62
35551456 2022
41
Destructive therapies for cutaneous warts: A review of the evidence. 62
36184865 2022
42
Successfully treated urethral condyloma acuminatum utilizing intraurethral self-application of 5-fluorouracil via Q-tip. 62
36245207 2022
43
Factors affecting children's HPV vaccination in Austria: Evidence from a parent survey. 62
36251011 2022
44
Condyloma acuminatum of the urinary tract demonstrates atypical squamous cells in urine cytology. 62
36244465 2022
45
Recurrent condyloma acuminatum after cryotherapy plus photodynamic therapy successfully treated by local hyperthermia: A case report. 62
35975429 2022
46
A new option for the treatment of condyloma acuminatum in the male urethra: Multimodal ultrasound image-guided scraping and photodynamic therapy (USP). 62
35753674 2022
47
ALA-PDT combined with oral acitretin in the treatment of refractory condyloma acuminatum in anal canal. 62
36183481 2022
48
Cryotherapy combined with photodynamic therapy for successful treatment of condyloma acuminatum in special sites such as the nipple and the nasal vestibule: A series of two case reports. 62
35644347 2022
49
Peripheral blood CD4+ T cell count predicts recurrence of condyloma acuminatum after photodynamic therapy in HIV-positive patients. 62
36052757 2022
50
Umbilical giant condyloma acuminatum. 62
34706983 2022

Variations for Anogenital Venereal Wart

Expression for Anogenital Venereal Wart

Search GEO for disease gene expression data for Anogenital Venereal Wart.

Pathways for Anogenital Venereal Wart

Pathways related to Anogenital Venereal Wart according to GeneCards Suite gene sharing:

(show all 39)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.8 UBE3A TP53 TLR9 TLR8 TLR7 TLR4
2
Show member pathways
13.74 CD4 CDKN2A GP5 H2AC18 IFNA1 IFNA6
3
Show member pathways
13.59 CCR6 CD4 IFNA1 IFNA6 IFNB1 IL2
4
Show member pathways
13.44 TP53 TLR9 TLR8 TLR7 TLR4 TLR3
5
Show member pathways
13.38 TP53 TLR9 TLR8 TLR7 TLR4 TLR3
6
Show member pathways
12.92 TP53 TLR4 IL2 IFNB1 IFNA6 IFNA1
7
Show member pathways
12.69 IL2 TLR3 TLR4 TLR7 TLR8 TLR9
8
Show member pathways
12.59 TLR3 TLR4 TLR7 TLR8 TLR9
9 12.54 TLR9 TLR8 TLR7 TLR3 IL2 IFNA1
10
Show member pathways
12.45 IFNA1 IFNB1 TLR3 TLR4 TLR7 TLR8
11
Show member pathways
12.43 TLR4 TLR3 IFNB1 IFNA6 IFNA1
12
Show member pathways
12.41 TLR9 TLR8 TLR7 TLR4 TLR3
13
Show member pathways
12.39 TLR9 TLR8 TLR7 TLR4 IFNB1
14
Show member pathways
12.38 TP53 TLR9 TLR8 TLR7 TLR4 TLR3
15
Show member pathways
12.37 TLR3 IFNB1 IFNA6 IFNA1
16
Show member pathways
12.22 TLR9 TLR8 TLR7 TLR4 TLR3
17 12.15 TP53 TLR9 TLR8 TLR7 TLR4 TLR3
18
Show member pathways
12.09 TP53 IL2 IFNB1 CDKN2A CD8A CD4
19
Show member pathways
12.08 TLR3 TLR4 TLR7 TLR8 TLR9
20 12 NCR1 IL2 GP5 CD8A CD4
21
Show member pathways
11.9 TLR9 TLR7 TLR4 TLR3 IFNB1
22 11.81 IFNB1 IFNA6 IFNA1
23 11.81 NCR1 IL2 CD8A CD4 CCR6
24
Show member pathways
11.78 TP53 TLR9 TLR8 TLR7 TLR4 TLR3
25 11.76 TLR4 TLR3 IL2 CD4
26
Show member pathways
11.76 TLR9 TLR8 TLR7 TLR4 TLR3 CD4
27
Show member pathways
11.74 IFNB1 CD8A CD4
28 11.72 TP53 TLR4 IFNB1
29 11.69 TLR7 TLR4 IL2
30 11.68 TP53 IL2 CDKN2A
31 11.63 TLR8 TLR7 TLR4
32 11.61 UBE3A TP53 CDKN2A
33 11.6 CD4 CD8A IFNB1 IL2 TLR7 TLR9
34 11.5 TLR8 TLR7 TLR4
35 11.45 TLR4 TLR3 IFNB1
37 11.25 IL2 IFNB1 CD4
38
Show member pathways
11.17 TLR9 TLR8 TLR7 TLR4 TLR3 IL2
39 10.73 TLR8 TLR7 TLR3

GO Terms for Anogenital Venereal Wart

Cellular components related to Anogenital Venereal Wart according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane GO:0016021 10.29 CCR6 CD4 CD8A GP5 GP6 NCR1
2 membrane GO:0016020 10.29 CCR6 CD4 CD8A GP5 GP6 NCR1
3 plasma membrane GO:0005887 10.03 CCR6 CD4 CD8A GP5 GP6 NCR1
4 plasma membrane GO:0005886 10.03 CCR6 CD4 CD8A GP5 GP6 NCR1
5 endosome membrane GO:0010008 9.96 TLR9 TLR8 TLR7 TLR4 TLR3
6 endolysosome membrane GO:0036020 9.23 TLR9 TLR8 TLR7 TLR3

Biological processes related to Anogenital Venereal Wart according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.57 UBE3A TP53 TLR9 TLR7 TLR4 TLR3
2 adaptive immune response GO:0002250 10.43 IL2 IFNB1 IFNA6 IFNA1 CD8A CD4
3 immune response GO:0006955 10.34 TLR9 TLR7 TLR4 TLR3 IL2 CD8A
4 defense response to virus GO:0051607 10.28 IFNA1 IFNA6 IFNB1 TLR3 TLR7 TLR8
5 positive regulation of inflammatory response GO:0050729 10.26 IL2 TLR3 TLR4 TLR7 TLR9
6 positive regulation of interleukin-6 production GO:0032755 10.25 TLR9 TLR8 TLR7 TLR4 TLR3
7 cellular response to mechanical stimulus GO:0071260 10.21 TLR8 TLR7 TLR4 TLR3
8 cellular response to virus GO:0098586 10.21 IFNA1 IFNA6 IFNB1 TLR3 TLR7
9 positive regulation of NIK/NF-kappaB signaling GO:1901224 10.19 TLR3 TLR4 TLR7 TLR9
10 humoral immune response GO:0006959 10.19 IFNB1 IFNA6 IFNA1 CCR6
11 positive regulation of interleukin-8 production GO:0032757 10.18 TLR9 TLR8 TLR7 TLR4 TLR3
12 positive regulation of chemokine production GO:0032722 10.17 TLR9 TLR7 TLR4 TLR3
13 positive regulation of B cell proliferation GO:0030890 10.14 TLR9 TLR4 IL2
14 positive regulation of interleukin-12 production GO:0032735 10.14 TLR9 TLR4 TLR3
15 type I interferon-mediated signaling pathway GO:0060337 10.14 IFNB1 IFNA6 IFNA1
16 response to exogenous dsRNA GO:0043330 10.14 IFNA1 IFNA6 IFNB1 TLR3
17 response to virus GO:0009615 10.13 TLR9 TLR8 TLR3 IFNB1
18 B cell proliferation GO:0042100 10.12 TLR4 IFNB1 IFNA6 IFNA1
19 natural killer cell activation GO:0030101 10.11 NCR1 IL2 IFNB1
20 T cell activation involved in immune response GO:0002286 10.1 IFNA1 IFNA6 IFNB1
21 positive regulation of macrophage cytokine production GO:0060907 10.1 TLR3 TLR4 TLR7
22 immune system process GO:0002376 10.1 TLR9 TLR8 TLR7 TLR4 TLR3 IL2
23 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 10.09 IFNB1 IFNA6 IFNA1
24 MyD88-dependent toll-like receptor signaling pathway GO:0002755 10.09 TLR9 TLR8 TLR4
25 natural killer cell activation involved in immune response GO:0002323 10.08 IFNB1 IFNA6 IFNA1
26 I-kappaB kinase/NF-kappaB signaling GO:0007249 10.06 TLR9 TLR8 TLR7 TLR4 TLR3
27 positive regulation of type II interferon production GO:0032729 10.03 IL2 TLR3 TLR4 TLR7 TLR8 TLR9
28 positive regulation of interferon-beta production GO:0032728 10.02 TLR9 TLR8 TLR7 TLR4 TLR3
29 I-kappaB phosphorylation GO:0007252 9.97 TLR9 TLR7 TLR4 TLR3
30 defense response GO:0006952 9.95 IFNA1 IFNA6 IFNB1 TLR3
31 positive regulation of toll-like receptor signaling pathway GO:0034123 9.94 TLR9 TLR3
32 regulation of dendritic cell cytokine production GO:0002730 9.88 TLR9 TLR4 TLR3
33 positive regulation of interferon-alpha production GO:0032727 9.85 TLR9 TLR8 TLR7 TLR4 TLR3
34 toll-like receptor signaling pathway GO:0002224 9.61 TLR9 TLR8 TLR7 TLR4 TLR3
35 response to external stimulus GO:0009605 9.02 TLR9 TLR8 TLR7 TLR4 TLR3

Molecular functions related to Anogenital Venereal Wart according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 pattern recognition receptor activity GO:0038187 9.73 TLR9 TLR8 TLR7
2 signaling receptor activity GO:0038023 9.73 CCR6 CD4 GP6 TLR3 TLR4 TLR8
3 type I interferon receptor binding GO:0005132 9.63 IFNB1 IFNA6 IFNA1
4 cytokine receptor binding GO:0005126 9.62 IFNB1 IFNA6 IFNA1
5 transmembrane signaling receptor activity GO:0004888 9.47 TLR9 TLR8 TLR7 TLR4 TLR3 GP6

Sources for Anogenital Venereal Wart

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....